MLQ.ai | Stocks

Gossamer Bio (GOSS) News

Price: $0.9583
Market Cap: $217.75M
Avg Volume: 1.63M

Country: US
Industry: Biotechnology
Sector: Healthcare

Beta: 1.88
52W Range: $0.499-1.55
Website: Gossamer Bio

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective April 7, 2025, to one non-executive employee of non-qualified stock option.

businesswire.com

Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago.

zacks.com

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. “As we close the book on 2024 and embrace the promise of 2.

businesswire.com

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far produced encouraging Phase 2 data and has an ongoing Phase 3 PROSERA trial for PAH. The main event comes with its topline results in Q4 2025. GOSS's pipeline includes a PH-ILD program slated to start Phase 3 in mid-2025. This program addresses a larger, high-mortality TAM.

seekingalpha.com

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented one oral presentation and three posters related to seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress that took place January 29th through February.

businesswire.com

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced one oral and three poster presentations related to seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress taking place January 29th through Febru.

businesswire.com

Gossamer Bio (GOSS) Upgraded to Buy: Here's What You Should Know

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com

All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com

After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)

Gossamer Bio (GOSS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

zacks.com

After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)

The heavy selling pressure might have exhausted for Gossamer Bio (GOSS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

zacks.com

Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.21 per share a year ago.

zacks.com

3 Penny Stocks To Buy With Just $50

Penny stocks are an interesting category. While they have the potential to produce significant long-run gains, you should never bet money on these stocks that you can't afford to lose.

247wallst.com

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and systemic absorption issues, unlike seralutinib, which targets key disease pathways effectively. Tyvaso DPI's success in PH-ILD highlights the unmet need, with Gossamer planning a Phase 3 trial for seralutinib in mid-2025.

seekingalpha.com

Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates

Gossamer Bio (GOSS) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.45 per share a year ago.

zacks.com

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Oppenheimer initiated coverage on Gossamer Bio Inc GOSS, a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.

benzinga.com

The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street

Do you have any penny stocks in your portfolio? If you don't, you might want to consider it with any speculative money sitting on the sidelines.

investorplace.com

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California. Details.

businesswire.com

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

Gossamer Bio said on Monday it will collaborate with Chiesi Group to develop and commercialize its drug seralutinib in multiple indications related to blood pressure conditions.

reuters.com

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

SAN DIEGO, Calif. & PARMA, Italy--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (“Gossamer”) (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and Chiesi Farmaceutici S.p.A (“Chiesi Group”), an international, research-focused biopharmaceutical group, today announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib. This glob.

businesswire.com

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the publication of its TORREY Phase 2 study manuscript in the Lancet Respiratory Medicine journal. The paper, titled "Seralutinib in Adults with Pulmonary Arterial Hypertensio.

businesswire.com

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors. Dr. Nathan is Medical Director of Inova's Advanced Lung Disease Program and Lung Transpla.

businesswire.com

Should You Buy Gossamer Bio (GOSS) After Golden Cross?

Gossamer Bio, Inc. (GOSS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GOSS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

zacks.com

GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023

Gossamer Bio (NASDAQ: GOSS ) just reported results for the fourth quarter of 2023. Gossamer Bio reported earnings per share of -21 cents.

investorplace.com

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

businesswire.com

7 Micro-Cap Stocks That Could Majorly Surprise Investors

Practically by default, your typical financial advisor will steer you clear of micro-cap stock surprises in favor of large-capitalization enterprises. Yes, the blue chips are reliable and dependable but this underlying predictability often comes at a cost: usually, you're not going to get rich off of them.

investorplace.com

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

businesswire.com

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

businesswire.com

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

businesswire.com

11 Top Penny Stocks To Buy Now According To Insiders

Ever wonder what signals to look for in the stock market today? Let's talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to watch.

pennystocks.com

5 Penny Stocks To Buy Now According To Insiders

Penny stocks are often priced under $5 per share. They attract traders seeking big gains.

pennystocks.com

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

businesswire.com

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary H.

businesswire.com

Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023

businesswire.com

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

businesswire.com

Gossamer Bio stock struggles from lack of near-term catalysts: analysts

Shares of Gossamer Bio fell Thursday, and the company earned a downgrade from analysts at UBS. Citing a "lack of near-term catalysts," the firm downgraded the biopharmaceutical company to Neutral from Buy and slashed its price target to $1.25 from $8.

proactiveinvestors.com

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced today that it will hold a conference call with PAH experts on Tuesday, July 25th at 10 a.m. EDT. Gossamer's management team will be joined by world-renowned PAH key opinion leaders, Dr. Ray Benza, Dr. Ardi Ghofrani, and Dr. Jim White to discuss the upcoming P.

businesswire.com

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

businesswire.com

Generational Equity Advises Wellspring Case Management in its Sale to Private Investors

DALLAS--(BUSINESS WIRE)--Generational Equity, a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client Wellspring Case Management, Inc. to Will Owen and Dane Fossee of Grosse Pointe, Michigan. The transaction closed May 2, 2023. Wellspring Case Management, Inc. (WCMI), located in Plymouth, Michigan, and founded in 2003, provides case management advocacy to people injured in car or motorcycle accidents. The Company helps injured clients access and manage appropriate medical care. WCMI has over 25 Case Managers from a variety of disciplines and backgrounds including: - Nursing - Speech-Language Pathology - Respiratory Therapy - Social Work - Occupational Therapy - Health and Wellness Each Case Manager continues the tradition of providing caring patient advocacy so that the Company’s clients and their loved ones can return as closely as possible to the life they knew before the accident. Generational Equity Executive Managing Director of M&A – Central Region, Michael Goss, Joe Hige, a Generational Group Authorized Affiliate, with the support of Vice President, M&A, Lance Thomasson successfully closed the deal. Executive Managing Director, Bill Kushnir established the initial relationship with WCMI. About Generational Equity Generational Equity, Generational Capital Markets (member FINRA/SIPC), Generational Wealth Advisors, Generational Consulting Group, and DealForce are part of the Generational Group, which is headquartered in Dallas and is one of the leading M&A advisory firms in North America. With more than 350 professionals located throughout 16 offices in North America, the companies help business owners release the wealth of their business by providing growth consulting, merger, acquisition, and wealth management services. The Generational suite of advisory services includes strategic and tactical growth consulting, exit planning education, business valuation, value enhancement strategies, M&A services, and wealth management. The M&A Advisor named Generational Equity Investment Banking Firm of the Year three years in a row, Valuation Firm of the Year in 2020, and North American Investment Bank of the Year in 2022 as well as Consulting Firm of the Year. The Global M&A Network named Generational USA Investment Bank of the Year in 2023. For more information visit https://www.genequityco.com/ or the Generational Equity press room.

businesswire.com

Matthews™ Announces Opening of New York Office

NEW YORK--(BUSINESS WIRE)--Matthews Real Estate Investment Services™, a commercial real estate investment services and technology firm, announced the opening of its New York office at 575 Fifth Avenue, #2810. The office is the first New York office for the Nashville-based brokerage and the 18th nationally. Matthews™ set forth an aggressive national expansion plan in late 2022 and has since opened four offices, with plans to launch three additional offices in the next six months. Less than two blocks from Rockefeller Center, the Fifth Avenue mixed-use workspace features on-site retail, dining, and collaborative office suites. Leasing approximately 6,200 square feet, Matthews’ agents, employees, and clients will be within minutes of the city’s global destinations and transportation hubs. Associate Market Leader DeWitt Goss will lead growth initiatives within the New York office. "Matthews™ and New York City have been on a collision course since our founding in 2015,” Goss said. “At Matthews™, we outhustle, outwork, and out desire our competitors, which is exactly what New York stands for. The opportunity this market brings is unlike anywhere else, which also goes for talent. While we respect the inherent challenges unique to this market, we plan to recruit the best in NYC commercial real estate to join us.” Matthews™ has exponentially grown its presence through office openings and high-level recruiting. Founded in Los Angeles, Matthews™ grew to be one of the most powerful brokerage firms in the U.S. in just eight years. The brokerage has grown its footprint by at least 20 percent year-over-year since 2015. “Starting in LA, we’ve opened an office in almost every major market on the West Coast, Southwest, Midwest, and Southeast,” President David Harrington said. “It was time for us to enter New York, the country's largest and most competitive real estate market. Our history has repeatedly shown that we enter a metro, take market share, and provide superior service to not only clients, but also to our agents.” For more information or to contact a Matthews™ specialized agent, please visit www.matthews.com. About Matthews™ Matthews Real Estate Investments Services™, a commercial real estate investment services and technology firm, holds recognition as an industry leader in investment sales, leasing, and debt and structured finance. Based out of Nashville, TN, and strategically positioned with over 500 agents and support staff in 15+ offices across the United States, Matthews™ continues to focus on expansion into new markets. For more information, please visit www.matthews.com.

businesswire.com

Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the first quarter ended March 31, 2023, and provided a business update. “Our team continues to build momentum across multiple fronts following the positive results from our Phase 2 TORREY study of seralutinib in PAH patients. With recent feedback from both the FDA and EMA, we are well positioned to commence our registration program,” said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer. “We remain on track to begin our Phase 3 clinical trial of seralutinib in the coming months, moving one step closer towards our goal of bringing a potential new medicine to patients suffering from PAH.” “Additionally, we made the difficult decision to undergo an operational restructuring and headcount reduction to prioritize resources around the development of seralutinib. We believe that this restructuring was a necessary step to focus the organization on activities which maximize the potential of seralutinib. We truly appreciate the hard work and dedication of all of our employees, past and present.” Seralutinib (GB002): Inhaled PDGFR, CSF1R and c-KIT Inhibitor for PAH Gossamer has successfully concluded an End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA) and the Scientific Advice process with the European Medicines Agency (EMA) following the completion of its positive Phase 2 TORREY Study in patients with PAH. The Company has reached agreement with both FDA and EMA regarding key design elements of the Phase 3 program and expects to commence a single registrational Phase 3 PAH clinical trial in the third quarter of 2023. The planned Phase 3 clinical trial will be a randomized, double-blind, placebo-controlled, global clinical trial in PAH patients. Patients will be randomized to receive either seralutinib or placebo, in addition to their background PAH therapies. Based on FDA and EMA feedback, we will test a single dose of 90 mg, twice daily versus placebo. The primary endpoint of the trial will be change in six-minute walk distance from baseline. Upon completion of the 24-week blinded portion of the Phase 2 TORREY Study, patients were able to enroll into an open-label extension trial. Gossamer plans to report initial results from this ongoing open-label extension trial in the middle of 2023. Clinical development of seralutinib for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) is expected to begin in the first half of 2024. Corporate Updates As part of a structural reorganization to center Gossamer around seralutinib and its continued development in PAH, Gossamer reduced its headcount by over 25%. Further development of all clinical and pre-clinical product candidates, outside of seralutinib, has been terminated, and strategic options are being assessed for those candidates. Gossamer is working diligently with affected employees to assist in their transition to new opportunities. Financial Results for Quarter Ended March 31, 2023 Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of March 31, 2023, were $201.9 million. The Company expects the combination of current cash, cash equivalents and marketable securities will be sufficient to fund operations through at least the next 12 months from the date our first quarter 2023 financial statements were available to be issued. Research and Development (R&D) Expenses: For the quarter ended March 31, 2023, R&D expenses were $37.8 million, compared to $42.3 million for the same period in 2022. General and Administrative (G&A) Expenses: For the quarter ended March 31, 2023, G&A expenses were $10.1 million, compared to $12.0 million for the same period in 2022. Net Loss: Net loss for the quarter ended March 31, 2023, was $49.2 million, or $0.52 per share, compared to a net loss of $57.8 million, or $0.76 per share, for the same period in 2022. About Gossamer Bio Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension. Forward-Looking Statements Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the anticipated timing of initiation and enrollment of clinical trials for seralutinib; including the expected initiation of a Phase 3 clinical program for seralutinib; the trial design of such Phase 3 clinical trial of seralutinib, plans to advance seralutinib in PH-ILD; expectations on the timing of data readouts from our clinical studies, including our Phase 2 open-label extension trial of for seralutinib; and the expected timeframe for funding our operating plan with current cash, cash equivalents and marketable securities. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer’s business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; later developments with and / or feedback from global regulatory authorities or the FDA that may differ from prior feedback which may alter our planned Phase 3 clinical trial design and timing of initiation thereof; disruption to our operations from the COVID-19 pandemic, including clinical trial delays; the Company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the results of preclinical studies and early clinical trials are not necessarily predictive of future results; the success of Gossamer’s clinical trials and preclinical studies for seralutinib; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of seralutinib that may limit their development, regulatory approval and/or commercialization, or may result in clinical holds, recalls or product liability claims; Gossamer’s ability to obtain and maintain intellectual property protection for seralutinib; Gossamer’s ability to comply with its obligations in collaboration agreements with third parties or the agreements under which it licenses intellectual property rights from third parties; unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may adversely affect our business and financial condition and the broader economy and biotechnology industry; Gossamer may use its capital resources sooner than it expects; and other risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Gossamer Bio Statement of Operations Condensed Consolidated Statement of Operations (in thousands, except share and per share amounts) (unaudited) Three months ended March 31, 2023 2022 Operating expenses: Research and development $ 37,795 $ 42,322 In process research and development 15 20 General and administrative 10,132 12,001 Total operating expenses 47,942 54,343 Loss from operations (47,942 ) (54,343 ) Other income (expense), net Interest income 587 224 Interest expense (3,500 ) (3,467 ) Other income (expense) 1,690 (199 ) Total other income (expense), net (1,223 ) (3,442 ) Net loss $ (49,165 ) $ (57,785 ) Net loss per share, basic and diluted $ (0.52 ) $ (0.76 ) Weighted average common shares outstanding, basic and diluted 94,870,293 75,894,692 Condensed Consolidated Balance Sheet (in thousands) BALANCE SHEET DATA: March 31, 2023 December 31, 2022 (unaudited) Cash, cash equivalents, and marketable securities $ 201,856 $ 255,678 Working capital 169,842 212,650 Total assets 219,906 272,450 Total liabilities 248,362 260,373 Accumulated deficit (1,081,388 ) (1,032,223 ) Total stockholders' equity (deficit) (28,456 ) 12,077

businesswire.com

Generational’s David Fergusson Named Investment Banker of the Year

DALLAS--(BUSINESS WIRE)--Generational Group, a leading full-service business advisory firm for middle market, privately held businesses is pleased to announce that David Fergusson was named Investment Banker of the Year at the 2023 5th Annual USA Middle Market M&A Atlas Awards. Generational was also honored with the following awards: Growth Equity Deal of the Year: Michael Goss and Lance Thomasson for IcyBreeze Cooling’s sale of a minority equity stake to Corbel Capital Partners Aerospace & Services Deal of the Year: Ahmad Behjati and Tristan Keeffe for Integral Industries acquisition by Enjet Aero All winners were recognized at the 5th Annual USA M&A Atlas Awards on April 27th, 2023, in Washington, D.C. at The Mayflower Hotel, hosted by the Global M&A Network. The Global M&A Network (GM&AN) is a diversified media company and the exclusive publisher of the popular “Top Dealmakers” lists. GM&AN also hosts the “Atlas Awards”, the world’s most prestigious awards for alternative investing, private equity, M&A, restructuring, transactional and business communities worldwide. In accepting the Investment Banker of the Year award, David Fergusson said: “I am truly honored to accept this award on behalf of our extraordinary Generational team.” “Our success is directly attributable to the founding principles that Ryan Binkley and John Binkley established when they started Generational,” Fergusson added. “As the firm has grown, so too have our achievements. The recognition our professionals have received—including recent awards as Investment Bank of The Year and Consulting Firm of the Year—are a testament to the power of holding true to the Golden Rule of respect, love and stewardship as our guiding light.” “We are guided by a firmwide commitment to unity, integrity, diligence and excellence.” "We are pleased that David was recognized by the Global M&A Network," said Brenen Hofstadter, Generational's Chief M&A Officer. "He is an exceptional dealmaker, business builder, and East Region leader." Ryan Binkley, President and CEO of Generational, stated, “it is truly a blessing to have so many members of our team recognized by the Global M&A Network. Their commitment to serve our clients is at the core of our success. Special congratulations to David Fergusson for his recognition in the highly competitive M&A industry.” About Generational Group Generational Equity, Generational Capital Markets (member FINRA/SIPC), Generational Wealth Advisors, Generational Consulting Group and DealForce are part of Generational Group, which is headquartered in Dallas, Texas. With more than 350 professionals located throughout 16 offices in North America, the companies help business owners release the wealth of their business by providing growth consulting, merger, acquisition, and wealth management services. The Generational suite of advisory services includes strategic growth consulting, exit planning education, business valuation, value enhancement strategies, M&A services, and wealth management. The M&A Advisor named Generational Equity Investment Banking Firm of the Year three years in a row, Valuation Firm of the Year in 2020, and North American Investment Bank of the Year in 2022 as well as Consulting Firm of the Year. For more information, visit https://www.genequityco.com/ or the Generational Equity press room.

businesswire.com

Generational Wins Multiple Global M&A Network Awards

DALLAS--(BUSINESS WIRE)--Generational Group, a leading full-service business advisory firm for middle market, privately held businesses is pleased to announce that it has won several honors at the 2023 5th Annual USA Middle Market M&A Atlas Awards. Generational was presented with the following awards: Investment Banker of the Year: David Fergusson Growth Equity Deal of the Year: Michael Goss and Lance Thomasson for IcyBreeze Cooling’s sale of minority equity stake to Corbel Capital Partners Aerospace & Services Deal of the Year: Ahmad Behjati and Tristan Keeffe for Integral Industries acquisition by Enjet Aero All winners were recognized at the 5th Annual USA M&A Atlas Awards on April 27th, 2023, in Washington, D.C. at The Mayflower Hotel, hosted by the Global M&A Network. The Global M&A Network (GM&AN) is a diversified media company and the exclusive publisher of the popular “Top Dealmakers” lists. GM&AN also hosts the “Atlas Awards”, the world’s most prestigious awards for alternative investing, private equity, M&A, restructuring, transactional and business communities worldwide. “It is wonderful to see so many of our M&A professionals recognized—and special congratulations to David Fergusson for being named Investment Banker of the Year. This is a recognition that he richly deserves for the leadership he provides to our team,” said Brenen Hofstadter, Generational’s Chief M&A Officer. Ryan Binkley, President and CEO of Generational, stated, “I am pleased that so many of our associates were recognized by The Global M&A Network. It is a real honor to serve our clients, and I am proud of the way our team of skilled professionals strive for excellence each and every day.” About Generational Group Generational Equity, Generational Capital Markets (member FINRA/SIPC), Generational Wealth Advisors, Generational Consulting Group and DealForce are part of Generational Group, which is headquartered in Dallas, Texas. With more than 350 professionals located throughout 16 offices in North America, the companies help business owners release the wealth of their business by providing growth consulting, merger, acquisition, and wealth management services. The Generational suite of advisory services includes strategic growth consulting, exit planning education, business valuation, value enhancement strategies, M&A services, and wealth management. The M&A Advisor named Generational Equity Investment Banking Firm of the Year three years in a row, Valuation Firm of the Year in 2020, and North American Investment Bank of the Year in 2022 as well as Consulting Firm of the Year. For more information, visit https://www.genequityco.com/ or the Generational Equity press room.

businesswire.com

EstrellaTV’S Award-Winning ‘Tengo Talento, Mucho Talento’ Ushers in Spring Changes With a New Season, New Judges, and a New Set

LOS ANGELES--(BUSINESS WIRE)--EstrellaTV’s award-winning entertainment competition series Tengo Talento, Mucho Talento returns for season 27 with a new cast, new set, and an energized pool of contestants trying to win the $100,000 grand prize. The series premiere is Monday, April 17, at 9 p.m./8 p.m. CT, and the show will air daily Monday through Thursday at that time. Returning judges Pepe Garza and acclaimed singer/artist Carolina Ross are joined by two new judges, comedian/actress La India Yuridia and award-winning singer/songwriter Joss Favela. Returning as a host for this season is award-winning artist Luis Coronel and Gisselle Bravo (Don Cheto Al Aire, Venga la Alegria). Los Pelillios return as the backstage reporters. Over 2500 people auditioned through in-person and online auditions over a 12‑week period that ended April 1. “We are taking a super-sized approach to this season,” said Enrique Guillen, Chief Content Officer, Estrella Media. “We had the opportunity to refresh the stage and judges panel, and the result is dynamite. The work of Anton Goss brings the show to a new production level. We are thrilled to welcome the gifted comedian La India Yuridia, and award-winning singer/songwriter Joss Favela to join the judge’s table this season. Together with Carolina and Pepe, we have the most entertaining and discerning panel in the business. They will dole out advice to our contestants with humor and gravitas, as they select the best performers throughout the competition.” About Estrella Media, Inc. Estrella Media is a leading Spanish-language media company and one of the largest U.S. producers of Spanish-language video and audio content for multiplatform distribution worldwide, with a library of over 20,000 hours of original video content. Estrella Media's content studio feeds its digital and linear media platforms, including EstrellaTV, its national broadcast television network that is seen on 15 owned or operated stations and 35 affiliated stations and through cable and satellite providers and digital streaming platforms; Estrella News, the first 24/7 Spanish-language multiplatform digital news network in the U.S.; Cine EstrellaTV, its Spanish-language movie channel; and Estrella Games, the first 24/7 curated Spanish-language game show channel in the U.S. Estrella Media's digital content reach is more than 4 billion minutes per month, viewed across its multiplatform media portfolio, including its FAST, AVOD, and streaming audio platforms. Estrella Media owns and operates 14 radio stations and the Don Cheto Radio Network with 35 affiliated stations throughout the U.S. and featuring one of the nation's most popular radio talents, Don Cheto. Estrella Media also produces large-scale music festivals, concerts, and special events throughout the U.S. In addition, Estrella Media produces podcasts for audio streaming and its music division, Estrella Media Music Entertainment, helps develop the next generation of Latin music stars. To learn more about Estrella Media and see company updates, please visit Estrella Media at estrellamedia.com, and follow us on Twitter @Estrellamedia_, Facebook @Estrellamediainc, and LinkedIn @Estrella Media, Inc.

businesswire.com

Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib

Merck's Sotatercept showed significant improvements in PAH patients in Phase 3 STELLAR trial with a primary endpoint of improvements in pulmonary vascular resistance, 6-minute walk distance, and NT-proBNP levels. Gossamer Bio's seralutinib showed clear efficacy in the Phase 2 TORREY trial, albeit not meeting expectations, and is moving forward with a revised Phase 3 trial.

seekingalpha.com

ReAlta Life Sciences Announces Poster Presentation at the American Thoracic Society 2023 Annual Meeting

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the American Thoracic Society 2023 Annual Meeting taking place in Washington, DC on May 19-24, 2023. RLS-0071, the Company’s complement inhibitor and innate anti-inflammatory product candidate, is being developed as a treatment for hypoxic ischemic encephalopathy and other rare diseases. The Phase 1b clinical trial (Protocol RLS-0071-103; NCT05351671) is a proof-of-mechanism (POM) study intended to establish RLS-0071 translatability from animal disease models of acute lung injury and other acute pulmonary exacerbations to humans by inhibiting neutrophil-mediated inflammation at the tissue level. The data will be presented by Prof. Dr. Jens M. Hohlfeld, Division Director of Airway Research at the Fraunhofer Institute for Toxicology and Experimental Medicine in Germany, and lead investigator on the Phase 1b trial. Details of the presentation: Title RLS-0071, A Novel Dual-targeting Anti-inflammatory Agent, Demonstrates Proof of Mechanism in a Phase 1b Inhaled LPS Study Significantly Reducing Lung Neutrophils Authors Jens M. Hohlfeld, Olaf Holz, Meike Müller, Saskia Carstensen, Linda Dell, Jessica Goss, Pam Hair, Philipp Badorrek, Kenji Cunnion, Ulrich Thienel Presentation Poster #P380; Walter E. Washington Convention Center, Area D, Hall C (Lower Level) Session C68 – Topics in Airway and Alveolar Epithelial Cell Biology Date/time Tuesday, May 23, 11:30 a.m. – 1:15 p.m. EDT About ReAlta Life Sciences ReAlta Life Sciences, Inc. is a clinical-stage biotech company dedicated to harnessing the power of the immune system to address life threatening rare diseases. The Company’s EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has received IND clearance, and Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates. The company launched in 2018 and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com.

businesswire.com

Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2022 and provided a business update. Clinical-Stage Product Candidate Updates Seralutinib (GB002): Inhaled PDGFR, CSF1R and c-KIT Inhibitor for Pulmonary Arterial Hypertension (PAH) Upon completion of the 24-week blinded portion of the Phase 2 TORREY Study, patients were able to enroll into an open-label extension trial. We anticipate reporting results from this ongoing open-label extension trial in the middle of 2023. We expect to commence a Phase 3 PAH clinical trial in the second half of 2023. The planned Phase 3 clinical trial will be a randomized, double-blind, placebo-controlled, global clinical trial in PAH patients. Patients will be randomized to receive either seralutinib or placebo, in addition to their background PAH therapies. Based on FDA feedback, we expect to test a single dose of 90 mg twice daily in the planned PAH Phase 3 clinical trial, and we expect the primary endpoint of the trial to be change in six-minute walk distance from baseline. However, the final trial design is subject to further feedback from global regulatory authorities. GB5121: Oral, CNS-Penetrant BTK Inhibitor for Primary CNS Lymphoma (PCNSL) Based upon the benefit / risk profile observed to date and a prioritization of resources to support the seralutinib program, Gossamer has decided to pause enrollment in the Phase 1b/2 STAR CNS study. Gossamer plans to discuss available data with the study’s Data Review Committee to determine next steps. Financial Results for Quarter and Full Year Ended December 31, 2022 Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of December 31, 2022, were $255.7 million. As a result, we expect our current cash, cash equivalents and marketable securities will be sufficient to fund operating and capital expenditures into the second half of 2024. Research and Development (R&D) Expenses: For the quarter ended December 31, 2022, R&D expenses were $41.5 million compared to R&D expenses of $40.9 million for the same period in 2021. R&D expenses for the full year ended December 31, 2022, were $170.9 million compared to $170.3 million for the full year ended December 31, 2021. General and Administrative (G&A) Expenses: For the quarter ended December 31, 2022, G&A expenses were $12.8 million compared to $10.7 million for the same period in 2021. G&A expenses for the full year ended December 31, 2022, were $47.6 million compared to $45.8 million for the full year ended December 31, 2021. Net Loss: Net loss for the three months ended December 31, 2022, was $55.8 million, or $0.59 per share, compared to a net loss of $56.3 million, or $0.74 per share, for the same period in 2021. Net loss for the full year ended December 31, 2022, was $229.4 million, or $2.71 per share, compared to a net loss of $234.0 million, or $3.13 per share, for the full year ended December 31, 2021. About Gossamer Bio Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases. Forward-Looking Statements Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the anticipated timing of initiation and enrollment of clinical trials for our product candidates, including the anticipated timing of initiation of the Phase 3 clinical trial of seralutinib in PAH; the trial design of such Phase 3 clinical trial of seralutinib based on regulatory feedback; plans to discuss our benefit / risk profile for GB5121 with our Data Review Committee, plans to advance our product candidates; expectations on the timing of data readouts from our clinical studies, including our Phase 2 open-label extension trial of seralutinib; and the expected timeframe for funding our operating plan with current cash, cash equivalents and marketable securities. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer’s business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; later developments with and / or feedback from global regulatory authorities or the FDA that may differ from prior feedback which may alter our planned Phase 3 clinical trial design and timing of initiation thereof; disruption to our operations from the COVID-19 pandemic, including clinical trial delays; the Company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the results of preclinical studies and early clinical trials are not necessarily predictive of future results; the success of Gossamer’s clinical trials and preclinical studies for its product candidates; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval and/or commercialization, or may result in clinical holds, recalls or product liability claims; Gossamer’s ability to obtain and maintain intellectual property protection for its product candidates; Gossamer’s ability to comply with its obligations in collaboration agreements with third parties or the agreements under which it licenses intellectual property rights from third parties; unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may adversely affect our business and financial condition and the broader economy and biotechnology industry; Gossamer may use its capital resources sooner than it expects; and other risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. GOSSAMER BIO, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENT DATA (UNAUDITED; IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) Three months ended December 31, Year ended December 31, STATEMENTS OF OPERATIONS DATA: 2022 2021 2022 2021 Operating expenses: Research and development $ 41,508 $ 40,932 $ 170,919 $ 170,267 In process research and development 15 15 65 75 General and administrative 12,834 10,714 47,609 45,782 Total operating expenses 54,357 51,661 218,593 216,124 Loss from operations (54,357 ) (51,661 ) (218,593 ) (216,124 ) Other income (expense) Interest income 594 236 1,583 761 Interest expense (3,457 ) (4,937 ) (13,880 ) (19,440 ) Other income (expense) 1,456 78 1,512 799 Total other expense, net (1,407 ) (4,623 ) (10,785 ) (17,880 ) Net loss $ (55,764 ) $ (56,284 ) $ (229,378 ) $ (234,004 ) Net loss per share, basic and diluted $ (0.59 ) $ (0.74 ) $ (2.71 ) $ (3.13 ) Weighted average common shares outstanding, basic and diluted 94,280,553 75,587,851 84,574,869 74,843,482 BALANCE SHEET DATA: December 31, 2022 December 31, 2021 Cash, cash equivalents, and marketable securities $ 255,678 $ 325,218 Working capital 212,650 291,921 Total assets 272,450 343,657 Total liabilities 260,373 222,194 Accumulated deficit (1,032,223 ) (811,534 ) Total stockholders' equity 12,077 121,463

businesswire.com

Generational Equity Advises Martin Pallet in its Sale to Burlington Capital Partners

DALLAS--(BUSINESS WIRE)--Generational Equity, a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client Martin Pallet, Inc. to Burlington Capital Partners LLC. The transaction closed February 28, 2023. The transaction was completed in partnership with Martin Pallet's management and Farragut Capital Partners. Located in Massillon, Ohio, Martin Pallet, Inc. (MPI) manufactures pallets, crates, and wood packaging products. Specifically, the Company produces a wide range of recycled pallets, new pallets, custom pallets, crates, as well as lumber and wood packaging materials. In addition, through related entities, MPI provides transportation, truck repair, and other complementary services. MPI is well known in the regional market and has an excellent reputation for the breadth of products offered, customer service, technical knowledge, and the timely delivery of products. Burlington Capital Partners (BCP), headquartered in Chicago, Illinois with an additional office in Cleveland, Ohio invests in family and founder-owned, lower middle market companies. BCP serves business owners in food and other mission-critical industries. They are equity investors that help lower middle market companies reach their potential. The Firm loves food and other businesses with strong repeat purchase dynamics run by great people who have an aligned vision for growth, integrity, and community. The investment will enable Martin Pallet to pursue growth initiatives and add-on acquisitions while providing liquidity to the owners. Richard Miller, co-owner and current CEO, will continue to lead sales and business development and BCP partner Tim Novak will assume a CEO role designed to drive operational efficiencies. BCP, led by partners Michael Baldwin and Tim Novak, effected a unique buyout intended to preserve Martin Pallet's culture while providing institutional capital and expertise. "We are very excited to partner with a wonderful ownership group that has been committed to a culture of quality, customer service, and employee satisfaction for over 20 years," said Mr. Novak. "BCP is honored to partner with such a mission-critical company and is excited to invest behind the key BCP themes of critical supply chain inputs and industry fragmentation," said Mr. Baldwin. "Pallets physically carry 80% of US commerce and Martin Pallet's flexibility with sizing, order quantities, and speed to delivery positions it well to support business customers within its serviceable radius." Farragut Capital Partners, located in Chevy Chase, Maryland provided both debt financing and an equity co-investment in support of the transaction. Alan Cuthbertson of Farragut said of the transaction, "Martin Pallet is a leader in its market serving a critical role in its customers' supply chains. We're excited to partner with BCP and the leadership team in capitalizing on the many opportunities ahead for growth and value creation." Generational Equity Executive Managing Director of M&A – Central Region, Michael Goss, and his team led by Senior Managing Director M&A, Doug Smith, with the support of Managing Director, M&A, Ryan Johnson successfully closed the deal. "We expect this partnership to enhance the growth and legacy of the company going forward,” said Smith. About Generational Equity Generational Equity, Generational Capital Markets (member FINRA/SIPC), Generational Wealth Advisors, Generational Consulting Group, and DealForce are part of the Generational Group, which is headquartered in Dallas and is one of the leading M&A advisory firms in North America. With more than 350 professionals located throughout 16 offices in North America, the companies help business owners release the wealth of their business by providing growth consulting, merger, acquisition, and wealth management services. Their six-step approach features strategic and tactical growth consulting, exit planning education, business valuation, value enhancement strategies, M&A transactional services, and wealth management. The M&A Advisor named the company Investment Banking Firm of the Year three years in a row, Valuation Firm of the Year in 2020, and North American Investment Bank of the Year in 2022 as well as Consulting Firm of the Year. The Global M&A Network named Generational USA Investment Bank of the Year in 2023. For more information visit https://www.genequityco.com/ or the Generational Equity press room.

businesswire.com

10 Top Penny Stocks To Watch With High Short Interest This Week

More short squeeze penny stocks to watch before February 2023. The post 10 Top Penny Stocks To Watch With High Short Interest This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

pennystocks.com

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore

Gossamer's TORREY showed stat sig PVR improvement, but the 6MWD was under what investors were hoping for; this led to a +70% decline in share price. Seralutnib is entering phase 3 with an adapted design (with more severe patients); although the success is less clear, any positive surprises can lead to a meaningful stock rally.

seekingalpha.com

4 Penny Stocks To Watch With High Short Interest In January 2023

Are these penny stocks ready to squeeze? The post 4 Penny Stocks To Watch With High Short Interest In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

pennystocks.com

Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com

Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Gossamer Bio (GOSS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

zacks.com

3 Short Squeeze Penny Stocks To Watch Before 2023

Short squeeze penny stocks to watch. The post 3 Short Squeeze Penny Stocks To Watch Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

pennystocks.com

Penny Stocks Vs. Blue Chips, 3 Main Differences

Understand these key penny stocks vs. blue chips differences The post Penny Stocks Vs.

pennystocks.com

Penny Stocks To Buy Now? 6 Short Squeeze Stocks To Watch

Penny stocks to watch with higher short interest right now. The post Penny Stocks To Buy Now?

pennystocks.com

Penny Stocks To Buy Now? 3 Short Squeeze Stocks To Watch

Penny stocks to watch with higher short interest right now. The post Penny Stocks To Buy Now?

pennystocks.com

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

Gossamer Bio, Inc.'s lead candidate - Seralutinib, indicated for Pulmonary Arterial Hypertension - met its primary endpoint in the Phase 2 TORREY study. Nevertheless, investors dumped the stock - due to Seralutinib's perceived inferiority to Merck's Sotatercept.

seekingalpha.com

Gossamer Bio tumbles as hypertension drug underperforms rival product in Phase 2 trial

Gossamer Bio Inc stock lost three quarters of its value today as the market questioned the performance of the company's experimental hypertension drug in a Phase 2 clinical trial despite an upbeat assessment from the company. “We are very pleased to share that seralutinib significantly improved hemodynamic, biomarker, and right heart structural and functional measures in a heavily treated pulmonary arterial hypertension patient population,” said Faheem Hasnain, CEO of Gossamer.

proactiveinvestors.ca

Why Is Gossamer Bio (GOSS) Stock Down Over 70% Today?

Gossamer Bio (NASDAQ: GOSS ) is one of the top-trending tickers on social media today, and its shares are plunging more than 70%. The company announced that a trial of its drug for hypertension, seralutinib, had met the primary goal in a Phase 2 trial.

investorplace.com

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

Shares of Gossamer Bio Inc. GOSS, +2.99% plunged 64.5% in premarket trading on Tuesday after Wall Street analysts questioned the performance of the company's experimental hypertension drug in a Phase 2 clinical trial. Though Gossamer said the drug, seralutinib, met the primary endpoint in a Phase 2 clinical trial, SVB Securities analyst Joseph Schwartz told investors that the therapy didn't outperform Merck & Co. Inc.'s MRK, -0.03% sotatercept.

marketwatch.com

What Makes Gossamer Bio (GOSS) a New Buy Stock

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com

This little-known biopharma stock could rally 70%: Goldman Sachs

Gossamer Bio Inc (NASDAQ: GOSS) is in the green on Thursday after a Goldman Sachs analyst said the stock is ready for another huge move to the upside.

invezz.com

Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy

Does Gossamer Bio (GOSS) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com

How to Find Penny Stocks to Buy in Summer 2022

Use these tips to find penny stocks to buy this Summer The post How to Find Penny Stocks to Buy in Summer 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

pennystocks.com

Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program

Gossamer Bio Inc (NASDAQ: GOSS) shares are falling after announcing topline results from its Phase 2 SHIFT-UC Study trial of GB004 in patients with mild-to-moderate active ulcerative colitis (UC). Neither GB004 treatment arm met the primary or secondary endpoints at week 12.

benzinga.com

Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a business update. “After a considerable amount of planning and effort, the Gossamer team is excited to enter 2022 with two ongoing Phase 2 trials expected to readout this year,” said Faheem Hasnain, Co-Founder, Chairman and Chief Executive Officer of Gossamer Bio. “In the near term, we are eager to review GB004 Phase 2 SHIFT-UC 12-week topline data in patients with mild-to-moderate ulcerative colitis in the second quarter. We believe that, in contrast to other IBD therapies, GB004 has the potential to restore the epithelial barrier without systemic immune suppression. If this thesis bears out, GB004 could address the large swath of ulcerative colitis patients who are reticent to progress to systemic immunomodulatory or biologic agents, despite their disease being uncontrolled by 5-ASA therapy.” Clinical-Stage Product Candidate Updates GB004: Oral HIF-1α Stabilizer for Inflammatory Bowel Disease (IBD) Primary endpoint week 12 topline data from the Phase 2 SHIFT-UC study in patients with mild-to-moderate ulcerative colitis (UC) are expected in the second quarter of 2022. Treat through week 36 topline data from the Phase 2 SHIFT-UC study in patients with mild-to-moderate UC are expected in the fourth quarter of 2022. Seralutinib (GB002): Inhaled PDGFR, CSF1R and c-KIT Inhibitor for Pulmonary Arterial Hypertension (PAH) Enrollment ongoing in the TORREY Study, a Phase 2 clinical trial in patients with PAH whose disease has progressed despite standard-of-care therapy. The primary endpoint is change in pulmonary vascular resistance from baseline at week 24. Topline data from the TORREY study are expected in the second half of 2022, subject to developments in the ongoing COVID-19 pandemic. GB5121: Oral, CNS-Penetrant BTK Inhibitor for Primary CNS Lymphoma (PCNSL) An investigational new drug (IND) application for GB5121 is now active, following a fourth quarter filing with the U.S. Food and Drug Administration (FDA). Gossamer expects to initiate a global Phase 1b/2 clinical trial of GB5121 in PCNSL patients in the first half of 2022. Financial Results for Quarter and Full Year Ended December 31, 2021 Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of December 31, 2021, were $325.2 million. As a result, we currently expect cash, cash equivalents and marketable securities, and access to our debt facility will be sufficient to fund operating and capital expenditures into the second half of 2023. Research and Development (R&D) Expenses: For the quarter ended December 31, 2021, R&D expenses were $40.9 million compared to R&D expenses of $38.9 million for the same period in 2020. R&D expenses for the full year ended December 31, 2021, were $170.3 million compared to $160.9 million for the full year ended December 31, 2020. The increase was primarily attributable to an increase of clinical trial and preclinical study costs associated with seralutinib, GB004, GB5121, and preclinical programs. This increase was partially offset by decreases in clinical trial and preclinical study costs related to GB001 and GB1275. In-Process Research and Development (IPR&D) Expenses: There were no significant IPR&D expenses for the quarter and year ended December 31, 2021. For the quarter ended December 31, 2020, IPR&D expenses were $5.3 million. IPR&D expenses for the full year ended December 31, 2020, were $23.4 million. General and Administrative (G&A) Expenses: For the quarter ended December 31, 2021, G&A expenses were $10.7 million compared to $15.9 million for the same period in 2020. G&A expenses for the full year ended December 31, 2021, were $45.8 million compared to $49.7 million for the full year ended December 31, 2020. Net Loss: Net loss for the three months ended December 31, 2021, was $56.3 million, or $0.74 per share, compared to a net loss of $64.6 million, or $1.05 per share, for the same period in 2020. Net loss for the full year ended December 31, 2021, was $234.0 million, or $3.13 per share compared to a net loss of $243.4 million, or $3.55 per share, for the full year ended December 31, 2020. Conference Call and Webcast Gossamer’s management team will host a conference call and live audio webcast at 4:30 p.m. ET today, Thursday, March 3, to discuss its fourth quarter and full year 2021 financial results and provide a corporate update. The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com. Alternatively, the conference call may be accessed through the following: Conference ID: 2791984 Domestic Dial-in Number: (833) 646-0603 International Dial-in Number: (929) 517-9782 Live Webcast: https://edge.media-server.com/mmc/p/ci4evdm2 A replay of the audio webcast will be available for 30 days on the “Investors” section of the Company's website, www.gossamerbio.com. About Gossamer Bio Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases. Forward-Looking Statements Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the anticipated timing of initiation and enrollment of clinical trials for our product candidates, including ongoing enrollment in the Phase 2 TORREY Study for seralutinib; plans to advance our product candidates; expectations on the timing of data readouts from our clinical studies; the potential clinical benefits, safety profile and market potential of our product candidates; the potential of our product candidates to benefit high unmet need patient populations; the expected impact of COVID-19; and the expected timeframe for funding our operating plan with current cash, cash equivalents and marketable securities. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer’s business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; disruption to our operations from the ongoing COVID-19 pandemic, including clinical trial delays and clinical site staff shortages; the Company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the results of preclinical studies and early clinical trials are not necessarily predictive of future results; the success of Gossamer’s clinical trials and preclinical studies for its product candidates; interim results do not necessarily predict final results and one or more of the outcomes may materially change as the trial continues and more patient data become available and following more comprehensive audit and verification procedures; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Gossamer’s ability to obtain and maintain intellectual property protection for its product candidates; Gossamer’s ability to comply with its obligations in collaboration agreements with third parties or the agreements under which it licenses intellectual property rights from third parties; Gossamer may use its capital resources sooner than it expects; potential impacts to the week 36 results from the Phase 2 SHIFT-UC study due to the conflict in Ukraine; and other risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. GOSSAMER BIO, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENT DATA (UNAUDITED; IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) Three months ended December 31, Year ended December 31, STATEMENTS OF OPERATIONS DATA: 2021 2020 2021 2020 Operating expenses: Research and development $ 40,932 $ 38,910 $ 170,267 $ 160,854 In process research and development 15 5,300 75 23,380 General and administrative 10,714 15,876 45,782 49,728 Total operating expenses 51,661 60,086 216,124 233,962 Loss from operations (51,661 ) (60,086 ) (216,124 ) (233,962 ) Other income (expense) Interest income 236 366 761 3,442 Interest expense (4,937 ) (4,753 ) (19,440 ) (12,666 ) Other income (expense) 78 (131 ) 799 (174 ) Total other expense, net (4,623 ) (4,518 ) (17,880 ) (9,398 ) Net loss $ (56,284 ) $ (64,604 ) $ (234,004 ) $ (243,360 ) Net loss per share, basic and diluted $ (0.74 ) $ (1.05 ) $ (3.13 ) $ (3.55 ) Weighted average common shares outstanding, basic and diluted 75,587,851 61,282,084 74,843,482 68,510,260 BALANCE SHEET DATA: December 31, 2021 December 31, 2020 Cash, cash equivalents, and marketable securities $ 325,218 $ 512,628 Working capital 291,921 483,672 Total assets 343,657 539,433 Total liabilities 222,194 218,749 Accumulated deficit (811,534 ) (577,530 ) Total stockholders' equity 121,463 320,684

businesswire.com

Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022

businesswire.com

Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q3 2021 Results - Earnings Call Transcript

seekingalpha.com

Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021

businesswire.com

Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the addition of two CNS-penetrant Bruton's tyrosine kinase (BTK) inhibitors to its product candidate pipeline. Gossamer plans to initiate first-in-human studies of the first of these candidates, GB5121, in the fourth quarter of 2021. G

businesswire.com

Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021

businesswire.com

Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role

businesswire.com

Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q2 2021 Results - Earnings Call Transcript

seekingalpha.com

Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021

businesswire.com

Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn's and Colitis Organisation

businesswire.com

Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer

businesswire.com

Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Luisa Salter-Cid, Ph.D., Gossamer's Chief Scientific Officer, is resigning from Gossamer effective April 30, 2021. On that date, Laura Carter, Ph.D., currently Gossamer's Senior Vice President, Research & Translational Biology

businesswire.com

Gossamer Bio Announces Promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs. In this role, Ms. Peterson will continue to lead Gossamer's Regulatory and Quality functions, tasked with strategizing and implementing global regulatory

businesswire.com

Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical's Razuprotafib in I-SPY COVID Trial

SAN FRANCISCO and CINCINNATI, March 5, 2021 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the Aerpio Pharmaceuticals drug, razuprotafib. Razuprotafib was chosen for testing in the I-SPY COVID...

prnewswire.com

Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q4 2020 Results - Earnings Call Transcript

seekingalpha.com

Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2020 and provided a business update. “The Gossamer team enters 2021 excited and focused on clinical trial execution,” said Faheem Hasnain, Co-Founder, Chairman and Chief Executive Officer of Gossamer. “Both seralutinib and GB004 are potentially paradigm shifting product candidates in indications of significant unmet patient need, and I am very proud of our team’s ongoing efforts to conduct our Phase 2 proof-of-concept studies for these programs despite the challenges of the pandemic.” Clinical-Stage Product Candidate Updates Seralutinib (GB002): Inhaled PDGFR, CSF1R and c-KIT Inhibitor for PAH Enrollment ongoing in the TORREY Study, a Phase 2 clinical trial in patients with PAH whose disease has progressed despite standard-of-care therapy. The primary endpoint is change in pulmonary vascular resistance (PVR) from baseline at week 24. Topline data from the TORREY study are expected in the first half of 2022, subject to developments in the ongoing COVID-19 pandemic. Key opinion leader-led webcast and presentation regarding PAH and seralutinib (GB002) held on December 15, 2020 available through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com. GB004: Oral HIF-1α Stabilizer for Inflammatory Bowel Disease (IBD) Enrollment ongoing in the SHIFT-UC Study, a Phase 2 clinical trial in patients with active UC despite treatment with 5-ASAs. The primary endpoint is proportion of patients with clinical remission at week 12. Topline data from the SHIFT-UC study are expected in the first half of 2022, subject to developments in the ongoing COVID-19 pandemic. Key opinion leader-led webcast and presentation regarding IBD and GB004 held on February 18, 2021 available through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com. GB1275: Oral CD11b Modulator for Oncology Indications Enrollment ongoing in a Phase 1 expansion cohort studying the recommended Phase 2 dose in KEYNOTE-A36, a Phase 1/2 clinical trial, including patients with gastric or esophageal cancer who have progressed after initial response to anti-PD-1 therapy and patients with advanced MSS colorectal cancer. Further Phase 1 data expected from this study in 2021. GB001: Oral DP2 Antagonist for Eosinophilic Asthma Gossamer engaged with the FDA and the EMA about the clinical development path in asthma, and based off those interactions, Gossamer believes that there is a viable clinical development path for GB001, or its backup molecule, in asthma. Gossamer does not currently plan to move forward with GB001, or its backup molecule, in further clinical trials without a partner. Financial Results for Quarter and Full Year Ended December 31, 2020 Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of December 31, 2020, were $512.6 million. As a result, we currently expect cash, cash equivalents and marketable securities, and access to our debt facility will be sufficient to fund operating and capital expenditures into the second half of 2023. Research and Development (R&D) Expenses: For the quarter ended December 31, 2020, R&D expenses were $38.9 million compared to R&D expenses of $42.6 million for the same period in 2019. R&D expenses for the full year ended December 31, 2020, were $160.9 million compared to $143.4 million for the full year ended December 31, 2019. The increases were primarily due to an increase in expenses for GB004, seralutinib, GB1275 and preclinical programs. In-Process Research and Development (IPR&D) Expenses: For the quarter ended December 31, 2020, IPR&D expenses were $5.3 million compared to $1.6 million for the same period in 2019. IPR&D expenses for the full year ended December 31, 2020, were $23.4 million compared to $3.6 million for the full year ended December 31, 2019. The increases were primarily attributable to a $15.0 million payment to Aerpio in connection with the amendment to the in-license agreement of GB004 in 2020 and a milestone payment of $5.0 million in connection with the initiation of the first Phase 2 clinical trial of seralutinib in 2020. General and Administrative (G&A) Expenses: For the quarter ended December 31, 2020, G&A expenses were $15.9 million compared to $11.6 million for the same period in 2019. G&A expenses for the full year ended December 31, 2020, were $49.7 million compared to $39.1 million for the full year ended December 31, 2019. The increases were primarily attributable to an increase in stock-based compensation costs and an increase in personnel-related costs. Net Loss: Net loss for the three months ended December 31, 2020, was $64.6 million, or $0.88 per share, compared to a net loss of $54.7 million, or $0.89 per share, for the same period in 2019. Net loss for the full year ended December 31, 2020, was $243.4 million, or $3.55 per share compared to a net loss of $180.3 million, or $3.29 per share, for the full year ended December 31, 2019. Conference Call and Webcast Gossamer’s management team will host a conference call and live audio webcast at 8:30 a.m. ET today, Thursday, February 25, to discuss its fourth quarter and full year 2020 financial results and provide a corporate update. The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com. Alternatively, the conference call may be accessed through the following: Conference ID: 5764004 Domestic Dial-in Number: (833) 646-0603 International Dial-in Number: (929) 517-9782 Live Webcast: https://edge.media-server.com/mmc/p/vsbk8uqe A replay of the audio webcast will be available for 30 days on the “Investors” section of the Company's website, www.gossamerbio.com. About Gossamer Bio Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases. Forward-Looking Statements Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the anticipated timing of enrollment of clinical trials for our product candidates; plans to advance our product candidates; expectations on the timing of data readouts from our clinical studies; the potential clinical benefits, safety profile and market potential of our product candidates; the potential of our product candidates to benefit high unmet need patient populations; the expected impact of COVID-19; and the expected timeframe for funding our operating plan with current cash, cash equivalents and marketable securities. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer’s business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; disruption to our operations from the recent global outbreak of the COVID-19 pandemic, including clinical trial delays; the Company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the results of preclinical studies and early clinical trials are not necessarily predictive of future results; the success of Gossamer’s clinical trials and preclinical studies for its product candidates; interim results do not necessarily predict final results and one or more of the outcomes may materially change as the trial continues and more patient data become available and following more comprehensive audit and verification procedures; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Gossamer’s ability to obtain and maintain intellectual property protection for its product candidates; Gossamer’s ability to comply with its obligations in collaboration agreements with third parties or the agreements under which it licenses intellectual property rights from third parties; Gossamer may use its capital resources sooner than it expects; and other risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. GOSSAMER BIO, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENT DATA (UNAUDITED; IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) Three months ended December 31, Year ended December 31, STATEMENTS OF OPERATIONS DATA: 2020 2019 2020 2019 Operating expenses: Research and development $ 38,910 $ 42,596 $ 160,854 $ 143,403 In process research and development 5,300 1,600 23,380 3,600 General and administrative 15,877 11,591 49,728 39,136 Total operating expenses 60,087 55,787 233,962 186,139 Loss from operations (60,087 ) (55,787 ) (233,962 ) (186,139 ) Other income (expense) Interest income 366 1,567 3,442 5,563 Interest expense (4,753 ) (715 ) (12,666 ) (1,938 ) Other income (expense) (130 ) 237 (174 ) 2,207 Total other income (expense), net (4,517 ) 1,089 (9,398 ) 5,832 Net loss $ (64,604 ) $ (54,698 ) $ (243,360 ) $ (180,307 ) Net loss per share, basic and diluted $ (0.88 ) $ (0.89 ) $ (3.55 ) $ (3.29 ) Weighted average common shares outstanding, basic and diluted 73,212,186 61,282,084 68,510,260 54,740,170 BALANCE SHEET DATA: December 31, 2020 December 31, 2019 Cash, cash equivalents, and marketable securities $ 512,628 $ 401,766 Working capital 483,672 372,394 Total assets 539,433 426,604 Total liabilities 218,749 74,119 Accumulated deficit (577,530 ) (334,170 ) Total stockholders' equity 320,684 352,485

businesswire.com

Gossamer Bio to Announce Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25, 2021

businesswire.com

Gossamer Bio to Host Webcast Focused on its Inflammatory Bowel Disease Program, GB004, on February 18, 2021

businesswire.com

Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Tuesday, December 15, 2020 at 11:00am ET to discuss GB002, its inhaled PDGFR inhibitor, for the treatment of pulmonary arterial hypertension (PAH). This webc

businesswire.com

Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer

businesswire.com

Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q3 2020 Results - Earnings Call Transcript

seekingalpha.com

Market Intelligence

Workspace

Gossamer Bio (GOSS) News

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio (GOSS) Upgraded to Buy: Here's What You Should Know

All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy

After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)

After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)

Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates

3 Penny Stocks To Buy With Just $50

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Should You Buy Gossamer Bio (GOSS) After Golden Cross?

GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

7 Micro-Cap Stocks That Could Majorly Surprise Investors

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

11 Top Penny Stocks To Buy Now According To Insiders

5 Penny Stocks To Buy Now According To Insiders

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

Gossamer Bio stock struggles from lack of near-term catalysts: analysts

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

Generational Equity Advises Wellspring Case Management in its Sale to Private Investors

Matthews™ Announces Opening of New York Office

Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update

Generational’s David Fergusson Named Investment Banker of the Year

Generational Wins Multiple Global M&A Network Awards

EstrellaTV’S Award-Winning ‘Tengo Talento, Mucho Talento’ Ushers in Spring Changes With a New Season, New Judges, and a New Set

Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib

ReAlta Life Sciences Announces Poster Presentation at the American Thoracic Society 2023 Annual Meeting

Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Generational Equity Advises Martin Pallet in its Sale to Burlington Capital Partners

10 Top Penny Stocks To Watch With High Short Interest This Week

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore

4 Penny Stocks To Watch With High Short Interest In January 2023

Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?

Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

3 Short Squeeze Penny Stocks To Watch Before 2023

Penny Stocks Vs. Blue Chips, 3 Main Differences

Penny Stocks To Buy Now? 6 Short Squeeze Stocks To Watch

Penny Stocks To Buy Now? 3 Short Squeeze Stocks To Watch

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

Gossamer Bio tumbles as hypertension drug underperforms rival product in Phase 2 trial

Why Is Gossamer Bio (GOSS) Stock Down Over 70% Today?

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

What Makes Gossamer Bio (GOSS) a New Buy Stock

This little-known biopharma stock could rally 70%: Goldman Sachs

Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy

How to Find Penny Stocks to Buy in Summer 2022

Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program

Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update

Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022

Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q3 2021 Results - Earnings Call Transcript

Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021

Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208

Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021

Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role

Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q2 2021 Results - Earnings Call Transcript

Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021

Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn's and Colitis Organisation

Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer

Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer